About this item:

387 Views | 294 Downloads

Author Notes:

Correspondence: bdunlop@emory.edu; Tel.: +1-404-727-8474

B.W.D., H.S.M., and W.E.C. led the conduct of the PReDICT study.

P.E.P. and B.W.D. conducted the data analysis.

P.E.P. managed the literature searches and wrote the first draft of the manuscript.

V.A.R., J.J.R., E.H., and B.W.D. assessed the study patients.

All authors contributed to the manuscript and approved the final version.

See publication for full list of disclosures.


Research Funding:

This research was funded by the National Institutes of Health, grant numbers P50 MH077083, R01MH080880, UL1 RR025008, and M01 RR0039.

Forest Labs and Elli Lilly Inc. donated the study medications, escitalopram and duloxetine, respectively, but were otherwise uninvolved in study design, data collection, data analysis, or interpretation of findings.


  • adverse drug reaction
  • antidepressant
  • drug toxicity
  • medication adherence
  • serotonin uptake inhibitors

Temporal Profiles and Dose-Responsiveness of Side Effects with Escitalopram and Duloxetine in Treatment-Naïve Depressed Adults.


Journal Title:

Behavioral Sciences


Volume 8, Number 7


, Pages 64-64

Type of Work:

Article | Final Publisher PDF


Side effect profiles of antidepressants are relevant to treatment selection and adherence among patients with major depressive disorder (MDD), but several clinically-relevant characteristics of side effects are poorly understood. We aimed to compare the side effect profiles of escitalopram and duloxetine, including frequencies, time to onset, duration, dose responsiveness, and impact on treatment outcomes. Side effects occurring in 211 treatment-naïve patients with MDD randomized to 12 weeks of treatment with flexibly-dosed escitalopram (10⁻20 mg/day) or duloxetine (30⁻60 mg/day) as part of the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) study were evaluated. Escitalopram- and duloxetine-treated patients experienced a similar mean number of overall side effects and did not differ in terms of the specific side effects observed or their temporal profile. Experiencing any side effect during the first 2 weeks of treatment was associated with increased likelihood of trial completion (86.7% vs. 73.7%, p = 0.045). Duloxetine-treated patients who experienced dry mouth were significantly more likely to achieve remission than those who did not (73.7% vs. 44.8%, p = 0.026). Side effects that resolved prior to a dose increase were unlikely to recur after the increase, but only about 45% of intolerable side effects that required a dose reduction resolved within 30 days of the reduction. At the doses used in this study, escitalopram and duloxetine have similar side effect profiles. Understanding characteristics of side effects beyond simple frequency rates may help prescribers make more informed medication decisions and support conversations with patients to improve treatment adherence.

Copyright information:

© 2018 by the authors.

This is an Open Access work distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).
Export to EndNote